Zealand Pharma to participate in upcoming healthcare conferences in September 2023
07 sept. 2023 11h00 HE
|
Zealand Pharma
Press release – No. 10 / 2023 Zealand Pharma to participate in upcoming healthcare conferences in September 2023 Copenhagen, Denmark, September 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
31 août 2023 11h35 HE
|
Zealand Pharma
Company announcement – No. 33 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Total number of shares and voting rights in Zealand Pharma at August 31, 2023
31 août 2023 11h30 HE
|
Zealand Pharma
Company announcement – No. 32 / 2023 Copenhagen, Denmark, August 31, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on...
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
30 août 2023 01h33 HE
|
Zealand Pharma
Company announcement – No. 31 / 2023 Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism US FDA has granted priority review...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
25 août 2023 10h45 HE
|
Zealand Pharma
Company announcement – No. 30 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
24 août 2023 16h00 HE
|
Zealand Pharma
Company announcement – No. 29 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, August 24, 2023 – Zealand Pharma A/S...
Zealand Pharma Announces Financial Results for the First Half of 2023
17 août 2023 01h00 HE
|
Zealand Pharma
Company announcement - No. 28 / 2023 Zealand Pharma Announces Financial Results for the First Half of 2023 Strong progress across R&D pipeline and significant strengthening of the balance...
Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results
14 août 2023 11h05 HE
|
Zealand Pharma
Press Release – No. 9 / 2023 Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results Copenhagen, Denmark, August 14, 2023 – a Zealand...
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
03 juil. 2023 06h01 HE
|
Zealand Pharma
Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396...
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
30 juin 2023 13h32 HE
|
Zealand Pharma
Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S...